JCU - January 2022 - 13

1000214
URO
Journal of Clinical UrologyGhaed et al.
Randomized Controlled Trial
Efficacy of cystone versus tamsulosin
in treatment of stent-related lower
urinary tract symptoms
Mohammad Ali Ghaed1 , Reza Rezaei2,
Amineh Shafeinia3 and Robab Maghsoudi4
Abstract
Objective: Double-J stent is a common tool used in urological procedures that is inserted for 2-6 weeks, but it may
induce abdominal and flank pain, incontinence and irritative urinary symptoms. Alleviation of such symptoms would be
useful to improve the patients' quality of life. Accordingly, in this study, the efficacy of cystone versus tamsulosin in the
treatment of double-J stent-related lower urinary tract symptoms was determined.
Materials and methods: In this randomised clinical trial, 128 patients who required double-J stent insertion after
transureteral lithotripsy during 2018-2019 were enrolled. They were randomly assigned to receive either cystone,
tamsulosin, both, or placebo. The international prostate symptom score and visual analogue score data were recorded
at baseline, after 2 and 4 weeks across the groups.
Results: The international prostate symptom score and visual analogue score factors were statistically different
across the case groups receiving cystone, tamsulosin and both drugs versus placebo (P=0.001). Two weeks after drug
administration, the visual analogue score and international prostate symptom score were not statistically different in
the tamsulosin, cystone and dual therapy groups; however, after 4 weeks the cystone group had the lowest symptoms.
Conclusion: Both tamsulosin and cystone are efficient drugs which would relieve stent-related lower urinary tract
symptoms. The administration of cystone with or without tamsulosin for 4 weeks may have the best result in reducing
the visual analogue score and international prostate symptom score.
Level of evidence: Level I, 1b, therapeutic study, randomised controlled trial
Keywords
Cystone, tamsulosin, double-J stent, IPSS (international prostate symptom score), VAS (visual analogue score)
Date received: 23 September 2020; accepted: 27 January 2021
Introduction
Double-J is a useful stent for routine urological procedures
which has been used for many years.1 It is used to alleviate
ureteral obstruction and should remain for 4-6 weeks. 2 It
may induce some abdominal and flank pain, haematuria,
lower urinary tract symptoms and urinary tract infections.3
The main mechanisms related to stent symptoms is not yet
clear but pain and lower urinary symptoms may be related
to the double-J stent.4 For symptom relief, different agents
are administered.5 Some drugs such as alfa-blockers (tamsulosin)
and anti-cholinergics (solifenacin) are used for this
matter.5-7 Tamsulosin is a selective inhibitor of α1a/1d
1 Urology Department, Rasool Akram Medical Complex, Iran University
of Medical Sciences, Tehran, Iran
2 Student Research Committee, Iran University of Medical Sciences,
Tehran, Iran
3 Anesthesiology Department, Shahid Akbarabadi Hospital, Iran
University of Medical Sciences, Tehran, Iran
4 Urology Department, Firoozgar Hospital, Iran University of Medical
Sciences, Tehran, Iran
Corresponding author:
Mohammad Ali Ghaed, Urology Department, Rasool Akram Medical
Complex, Sattarkhan St., Tehran, Iran.
Email: ghaed1982@gmail.com
Journal of Clinical Urology
2022, Vol. 15(1) 13 -18
© British Association of
Urological Surgeons 2021
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/20514158211000214
journals.sagepub.com/home/uro
https://doi.org/10.1177/20514158211000214
https://uk.sagepub.com/en-gb/journals-permissions https://www.doi.org/10.1177/20514158211000214 https://journals.sagepub.com/home/uro

JCU - January 2022

Table of Contents for the Digital Edition of JCU - January 2022

Contents
JCU - January 2022 - Cover1
JCU - January 2022 - Contents
JCU - January 2022 - 2
JCU - January 2022 - 3
JCU - January 2022 - 4
JCU - January 2022 - 5
JCU - January 2022 - 6
JCU - January 2022 - 7
JCU - January 2022 - 8
JCU - January 2022 - 9
JCU - January 2022 - 10
JCU - January 2022 - 11
JCU - January 2022 - 12
JCU - January 2022 - 13
JCU - January 2022 - 14
JCU - January 2022 - 15
JCU - January 2022 - 16
JCU - January 2022 - 17
JCU - January 2022 - 18
JCU - January 2022 - 19
JCU - January 2022 - 20
JCU - January 2022 - 21
JCU - January 2022 - 22
JCU - January 2022 - 23
JCU - January 2022 - 24
JCU - January 2022 - 25
JCU - January 2022 - 26
JCU - January 2022 - 27
JCU - January 2022 - 28
JCU - January 2022 - 29
JCU - January 2022 - 30
JCU - January 2022 - 31
JCU - January 2022 - 32
JCU - January 2022 - 33
JCU - January 2022 - 34
JCU - January 2022 - 35
JCU - January 2022 - 36
JCU - January 2022 - 37
JCU - January 2022 - 38
JCU - January 2022 - 39
JCU - January 2022 - 40
JCU - January 2022 - 41
JCU - January 2022 - 42
JCU - January 2022 - 43
JCU - January 2022 - 44
JCU - January 2022 - 45
JCU - January 2022 - 46
JCU - January 2022 - 47
JCU - January 2022 - 48
JCU - January 2022 - 49
JCU - January 2022 - 50
JCU - January 2022 - 51
JCU - January 2022 - 52
JCU - January 2022 - 53
JCU - January 2022 - 54
JCU - January 2022 - 55
JCU - January 2022 - 56
JCU - January 2022 - 57
JCU - January 2022 - 58
JCU - January 2022 - 59
JCU - January 2022 - 60
JCU - January 2022 - 61
JCU - January 2022 - 62
JCU - January 2022 - 63
JCU - January 2022 - 64
JCU - January 2022 - 65
JCU - January 2022 - 66
JCU - January 2022 - 67
JCU - January 2022 - 68
JCU - January 2022 - 69
JCU - January 2022 - 70
JCU - January 2022 - 71
JCU - January 2022 - 72
JCU - January 2022 - 73
JCU - January 2022 - 74
JCU - January 2022 - 75
JCU - January 2022 - 76
JCU - January 2022 - 77
JCU - January 2022 - 78
JCU - January 2022 - Cover3
JCU - January 2022 - Cover4
https://www.nxtbookmedia.com